Related Experiment Video
Updated: Sep 26, 2026

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
Published on: April 4, 2019
Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus
1Dept. of Internal Medicine, Div. of Allergy and Immunology, Joy McCann Culverhouse Airway Disease Research Center, University of South Florida College of Medicine/VA Hospital, 12901 Bruce B. Downs Boulevard, Tampa, FL 33612, USA. smohapat@hsc.usf.edu
Abstract:
A number of approaches have been used in attempts to develop a safe and effective vaccine for respiratory syncytial virus (RSV) infection. This article describes an effective prophylactic intranasal gene transfer strategy utilizing chitosan-DNA nanospheres [the mucosal gene expression vaccine (MGXV)], containing a mixture of plasmid DNAs encoding RSV antigens. In a mouse model of RSV infection, a single administration of MGXV (25 microg/mouse) results in a significant reduction of viral titers and viral antigen load after acute RSV infection of these mice. MGXV-treated mice show no significant change in airway reactivity to methacholine and no apparent pulmonary inflammation. Together these results demonstrate the potential of MGXV against acute RSV infection.
Related Concept Videos
Respiratory Syncytial Virus Disease
Microorganisms in Medicine and Therapeutics
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

